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TREATMENT OF CARTILAGE LESIONS USING EXPANDED 
CARTILAGE CELLS SEEDED ON A THREE DIMENSIONAL 
FIBROUS SCAFFOLD BASED ON BENZYLIC ESTER OF 
HYALURONIC ACID -- PRELIMINARY CLINICAL RESULTS 
K-D Schatz 
Orthopaedics, University of Vienna, Austria 
Cartilage lesions of diarthroidal joints still represent a great chal- 
lenge for the orthopaedic surgeon as hyaline cartilage is well 
known for a poor capacity to heal. Tissue engineering of autolo- 
gous cartilage seems to be a promising method for repairing car- 
tilage defects in reconstructive surgery. However, the clinical 
experience with autologous cartilage implantation (ACI) has 
shown several imitations essentially related to complicated oper- 
ating procedures. To improve biological performance and surgical 
technique a smalt number of chondrocytes is initially isolated 
from a tiny cartilage biopsy. Then the cells are expanded in con- 
ventional monolayer cultures to provide a sufficient number of 
cells. Finally the cells are seeded into a scaffold structure to 
enable the organization of 3-dimensional configurations. After 
preparation of the lesion site the graft is directly adapted into the 
lesion without drilling. The graft then is fixed with a fibrin glue, no 
coverage of the defect with periosteum is performed. The redif- 
ferentiation potential of chondrocytes cultured within 3-D matri- 
ces made of biocompatible materials has been proved in recent 
studies. 
The current clinical experience is based on a 1.0 years follow-up 
of 13 patients treated at the Orthopaedic Department, University 
of Vienna. According to a prospective trial protocol the overall 
population was between 14 and 55 years. Knee joints were treat- 
ed without restrictions of size and number of cartilage defects or 
previous operations. Cartilage lesion grade III and IV according to 
the Outerbridge scale, Iocalisation on the medial or femoral 
condyle respectively patella lesions and a well balanced mechan- 
ical joint axis were further inclusion criteria. No cases of arthritis 
or infections respectively instable or malaligned knee joints were 
operated. The follow-up included MRI and clinical scores 
(Lysholm score and cartilage standard evaluation form) at 3, 6 
and 12 months. Study endpoint was defined with 3 years post- 
operatively. On the basis of the follow-up data available, patients 
showed immediate pain relief with good range of motion, no seri- 
ous adverse events related to the product was observed. A limit- 
ed number of minor adverse events were recorded. 
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CHARACTERIZATION OF THE CHONDROCYTE-SPECIFIC 
UPSTREAM PROMOTER REGION OF THE HUMAN COL9A1 
GENE 
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Medical School, Thomas Jefferson University, Philadelphia, 
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Aim: The aim of this study was to to characterize the upstream 
chondrocyte-specific (CSU) promoter region of the human 
COL9At gene. 
Methods: Computer analysis of the region from -890 bp to the 
transcriptional start site of the CSU promoter egion predicts at 
least 5 putative SOX/Sry binding sites. Electromobility shift 
assays with oligonucleotide probes encompassing the putative 
SOX/Sry binding sites were performed with bovine fetal chondro- 
cyte (BFC), human chondrosarcoma (HTB), rat chondrosarcoma 
(RCS) and NIH 3T3 nuclear extracts. Co-transfection analyses 
with full-length and deleted COL9A1 CSU-promoter/reporter 
constructs and a SOX9 expression plasmid were performed in 
HTB and RCS cells. 
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Results: Electromobility shift assays with oligonucleotide probes 
encompassing the putative SOX/Sry binding sites revealed spe- 
cific DNA-protein complexes with BFC, HTB and RCS nuclear 
extracts but not with NIH 3T3 nuclear extracts. The DNA-pretein 
complexes that formed with the BFC nuclear extract and the 
COL9AI CSU-promoter probes could be abrogated with an 84 bp 
probe containing the SOX9, SOX6 and L-SOX5 binding sites from 
the human COL2A1 enhancer in competition experiments. Co- 
transfection analyses showed that a COL9AI CSU- 
promoter/reporter construct containing the 5 putative SOX/Sry 
binding sites was activated 20-25 fold in HTB cells by a SOX9 
expression plasmid. A lower level (2-3 fold) of activation was seen 
in RCS cells by cotransfection presumably due to the presence of 
endogenous SOX9. In transient ransfection analyses, deletion of 
the most upstream putative SOX/Sry binding site resulted in a 
negligible decrease in activity whereas deletion of the region con- 
taining the proximal 4 of 5 putative SOX/Sry binding sites result- 
ed in a drastic (85%) decrease in activity in RCS cells. Both dele- 
tion constructs were activated by co-transfection with a SOX9 
expression plasmid in HTB cells. 
Conclusions: These results indicate that SOX9 is a potent acti- 
vator of the COL9A1 CSU-promoter egion and that the organi- 
zation of the CSUpromoter region is similar to that of the 
COL11A2 gene promoter. 
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LPS STIMULATION UPREGULATES MATRIX METALLOPRO- 
TEINASE-1, -3, p AND -13, CYCLOOXGENASE -2 AND 
AGGRECANASE-1 GENE EXPRESSION 
IN CULTURED BOVINE CHONDROCY'FES 
Xia-di Zhou, Loran Killar, Pin Lu 
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Objective: To understand the role of chondrocytes in cartilage 
homeostasis, we investigated gene expression levels of matrix r 
metalloproteinases (MMPs), cyctoocygenase (COX), aggrecanas- 
es, and iNOS in cultured bovine chondrocytes timulated with 
LPS. We also evaluated the efficacy of anti-inflammatory agents 
mesotrexate and dexamethasone  the above gene's upregula- 
tion. 
Method: Chondrocytes were isolated from calf cartilage through 
serial enzymatic digestion. Cultured bovine chondrocytes were 
stimulated with LPS w/o the treatment of either mesotrexate or 
dexamethasone. Chondrocytes were then lysed for RNA purifica- 
tion at different ime points. The target gene message was detect- 
ed through real-time PCR with specific primers. The data are pre- 
sented as fold increases over unstimulated cells. All data pre- 
sented here were representative of three independent studies. 
Results: LPS induced MMP-13, -3, -1, COX-2, aggrecanase-1 
and 2 gene expression upregulation in chondrocytes in a dose 
dependent manner but reached plateau at 1 p.g/rnl level. Among 
genes investigated, MMP-13 was most responsive to LPS and 
showed around 1000-800 fold elevation, MMP-3 and COX-2 
genes were around 100 fold increases, while MMP-1 showed only 
around 10-20 fold upregulation. Kinetic study showed that LPS- 
induced response peaked at 24 hours and diminished by 72 
hours, except aggarecanase-2 mRNA peaked at 72hours. mRNA 
levels of proteoglycan, type 11 collagen, iNOS were unchanged. 
Addition of dexamethasone strongly inhibited LPS-induced 
MMP-13, -3, and -I as well as COX-2 gene upregulation. 
Mesotrexate treatment partially inhibited LPS-induced MMP-13, - 
3, and-i gene expression but exacerbated aggracanase-1 expres- 
sion. Moreover, it did not affect elevated COX-2 gene expression. 
Conclusions: LPS stimulation was able to induce significant 
MMPs, cox-2 and aggarecanases gene upregulation in cultured 
bovine chondrocytes. Dexamethasone suppressed all target 
